Pi­lot project pro­vides a snap­shot of ef­fec­tive­ness of Pfiz­er’s PARP con­tender ta­la­zoparib

You can ex­pect some no­table re­search up­dates on the slate of late-stage PARP in­hibitors at this week­end’s an­nu­al Eu­ro­pean So­ci­ety of Med­ical On­col­o­gy meet­ing. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA